These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27521321)

  • 21. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Acute myeloid leukemia: a comprehensive review and 2016 update'.
    De Kouchkovsky I; Abdul-Hay M
    Blood Cancer J; 2016 Jul; 6(7):e441. PubMed ID: 27367478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Elderly Patients With Acute Myeloid Leukemia.
    Thomas X; Le Jeune C
    Curr Treat Options Oncol; 2017 Jan; 18(1):2. PubMed ID: 28144802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions.
    Rosenblat TL; Jurcic JG
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1189-213. PubMed ID: 22093583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging agents and regimens for AML.
    Liu H
    J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of AML: who do we really cure?
    Liesveld J
    Leuk Res; 2012 Dec; 36(12):1475-80. PubMed ID: 22938830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?
    Walter RB
    Curr Opin Hematol; 2016 Mar; 23(2):102-7. PubMed ID: 26766538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Webster JA; Pratz KW
    Leuk Lymphoma; 2018 Feb; 59(2):274-287. PubMed ID: 28573892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance therapy in AML: The past, the present and the future.
    Molica M; Breccia M; Foa R; Jabbour E; Kadia TM
    Am J Hematol; 2019 Nov; 94(11):1254-1265. PubMed ID: 31429099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in acute myeloid leukemia.
    Newell LF; Cook RJ
    BMJ; 2021 Oct; 375():n2026. PubMed ID: 34615640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-remission therapy for acute myeloid leukemia.
    Schlenk RF
    Haematologica; 2014 Nov; 99(11):1663-70. PubMed ID: 25420282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
    Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.
    Michaelis LC; Erba HP
    Curr Opin Hematol; 2015 Mar; 22(2):108-15. PubMed ID: 25603478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in acute myeloid leukemia.
    Kadia TM; Ravandi F; O'Brien S; Cortes J; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):139-51. PubMed ID: 25441110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
    Ravandi F; Jorgensen JL
    J Natl Compr Canc Netw; 2012 Aug; 10(8):1029-36. PubMed ID: 22878826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.